CFFT, Alnylam Collaborate to Discover RNAi Therapeutic for CF

Cystic Fibrosis Foundation Therapeutics (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation, and Alnylam Pharmaceuticals, a leading RNAi therapeutics company, have initiated a collaborative program to discover Direct RNAi therapeutics for the treatment of cystic fibrosis (CF).

Alnylam will apply RNAi technology toward the discovery of short interfering RNAs (siRNAs), the molecules that induce RNA interference, to restore protein function in CF. CFFT is expected to provide Alnylam with $1.5 million in up front and milestone-driven funding for the discovery effort, along with introductions to world-class CF academic researchers and access to critical research resources.